BGIM
ALXN

Boussard & Gavaudan Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-624,427
Closed -$115M – 161
2021
Q2 		$115M Sell
624,427
-83,948
-12% -$14.4M 10.9% 2
2021
Q1 		$109M Buy
+708,375
New +$110M 10.57% 2

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Boussard & Gavaudan Investment Management's ALXN Position: Q3 2021 in Review

Boussard & Gavaudan Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 624,427 shares — an estimated $115M sold.

Boussard & Gavaudan Investment Management first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $115M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Boussard & Gavaudan Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 624,427 Alexion Pharmaceuticals shares in Q3 2021, an estimated $115M.
  • Boussard & Gavaudan Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Boussard & Gavaudan Investment Management's Alexion Pharmaceuticals position peaked at $115M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q3 2021, filed 8 Nov 2021.